Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis

This study has been completed.
Sponsor:
Information provided by:
Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT00286351
First received: February 1, 2006
Last updated: April 20, 2007
Last verified: April 2007

February 1, 2006
April 20, 2007
January 2005
Not Provided
size of endometriomas after 2½ month of combined downregulation
Not Provided
Complete list of historical versions of study NCT00286351 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis
Not Provided

Does a combination of Arimidex and Zoladex make endometriomas shrink and how is the following IVF outcome

Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Endometriosis
Drug: Combined treatment with Arimidex and Zoladex before IVF
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
Not Provided
Not Provided

Inclusion Criteria:

  • Endometrioma(s)with a size of 20-70 mm, persisted for at least 3 cycles
  • Couples with indication and wish for IVF/ICSI
  • Age of women: 20-40 years
  • Regular menstrual cycle within normal range (21-35 days)
  • Body Mass Index (BMI): 18-30 kg/m2

Exclusion Criteria:

  • History with osteoporosis, liver-, kidney- or heart disease or thromboembolic disease
  • Treatment of endometriosis with GnRH agonist during the last 3 month
Female
20 Years to 40 Years
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT00286351
endo 220604
Not Provided
Not Provided
Rigshospitalet, Denmark
Not Provided
Principal Investigator: Kristine Lossl, medical doctor The Fertility Clinic, Copenhagen University Hospital Rigshospitalet
Rigshospitalet, Denmark
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP